DR Horton (NYSE:DHI) Downgraded to Neutral at Citigroup

DR Horton (NYSE:DHI – Get Free Report) was downgraded by Citigroup investment analysts from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, Briefing.com reports. They currently have a price target for the construction company’s shares of $156.00, down from their previous price target of $181.00. Citigroup’s price target would indicate a potential upside of 13.84% from the company’s current price.

DHI has been the subject of numerous other research reports. Keefe, Bruyette & Woods raised their price target on shares of DR Horton from $172.00 to $178.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 7. Bank of America lowered their price target on shares of DR Horton from $182.00 to $168.00 and set a “buy” rating for the company in a report on Friday, April 19. UBS Group raised their price target on shares of DR Horton from $192.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, April 19. Jefferies Financial Group raised their price target on shares of DR Horton from $141.00 to $153.00 and gave the company a “hold” rating in a report on Friday, April 19. Finally, Wedbush reaffirmed an “underperform” rating and set a $130.00 price target on shares of DR Horton in a research note on Thursday, April 18. Two equities analysts rated the stock “sell,” six gave a “hold” rating, and ten gave a “buy” rating. According to data from MarketBeat.com, DR Horton currently has an average rating of “hold” and a consensus price target of $156.75.

Read our latest analysis of DR Horton

DR Horton’s Action Results

Shares of DR Horton opened at $137.04 on Tuesday. The company has a market capitalization of $45.13 billion, a P/E ratio of 9.33, a PEG ratio of 0.70 and a beta of 1.71. DR Horton has a 52-week low of $100.08 and a 52-week high of $165.75. The company has a current ratio of 1.38, a current ratio of 7.35 and a debt-to-equity ratio of 0.24. The company has a 50-day moving average price of $145.10 and a 200-day moving average price of $148.62.

DR Horton (NYSE:DHI – Get Free Report) last released its financial results on Thursday, April 18. The construction company reported $3.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.08 by $0.44. The company had revenue of $9.11 billion for the quarter, compared to the consensus estimate of $8.15 billion. DR Horton had a return on equity of 21.32% and a net margin of 13.39%. The company’s revenue grew 14.2% year-over-year. During the same period last year, the company earned $2.73 EPS. Sell-side analysts are expecting DR Horton to post $14.26 EPS for the current year.

Internal Activity at DR Horton

In other news, Director Michael R. Buchanan sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, May 6. The shares were sold at an average price of $150.70, for a total transaction value of $301,400.00. Following the completion of the sale, the director now owns 1,703 shares of the company’s stock, valued at approximately $256,642.10. The sale was disclosed in legal documents filed with the Securities and Exchange Commission, which can be accessed through this link . In other news, Director Barbara K. Allen sold 363 shares of the company’s stock in a transaction that occurred on Tuesday, April 23. The shares were sold at an average price of $148.46, for a total transaction value of $53,890.98. Following the transaction, the director now directly owns 5,650 shares of the company’s stock, valued at approximately $838,799. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . Additionally, Director Michael R. Buchanan sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, May 6. The shares were sold at an average price of $150.70, for a total transaction value of $301,400.00. Following the transaction, the director now directly owns 1,703 shares of the company’s stock, valued at approximately $256,642.10. Disclosure of this sale can be found here . Insiders own 1.74% of the company’s stock.

Institutional investors rate DR Horton

Institutional investors recently changed their holdings in the company. Rise Advisors LLC acquired a new stake in DR Horton shares in the first quarter valued at approximately $27,000. RiverPark Advisors LLC acquired a new stake in DR Horton shares in the first quarter valued at approximately $29,000. Riverview Trust Co acquired a new position in DR Horton shares in the first quarter valued at approximately $30,000. Oakworth Capital Inc. acquired a new position in DR Horton shares in the fourth quarter valued at approximately $38,000. Finally, Private Wealth Management Group LLC acquired a new stake in DR Horton shares in the fourth quarter valued at approximately $42,000. 90.63% of the shares are owned by institutional investors and hedge funds.

DR Horton Company Profile

(Download the free report)

DR Horton, Inc. operates as a homebuilder in the East, North, Southeast, South Central, Southwest and Northwest regions of the United States. It engages in the acquisition and development of land; construction and sale of residential homes in 118 markets in 33 states under the DR

See also

Get daily news and reviews for DR Horton – Enter your email address below to receive a concise summary of the latest news and analyst ratings for DR Horton and related companies in MarketBeat.com’s FREE daily newsletter.